Free Trial
NASDAQ:XLO

Xilio Therapeutics Q1 2025 Earnings Report

Xilio Therapeutics logo
$0.88 -0.01 (-1.47%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$0.88 -0.01 (-1.00%)
As of 05/23/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xilio Therapeutics EPS Results

Actual EPS
-$0.18
Consensus EPS
$0.10
Beat/Miss
Missed by -$0.28
One Year Ago EPS
N/A

Xilio Therapeutics Revenue Results

Actual Revenue
$2.93 million
Expected Revenue
$42.00 million
Beat/Miss
Missed by -$39.07 million
YoY Revenue Growth
N/A

Xilio Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Earnings Documents

Xilio Therapeutics Earnings Headlines

Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
See More Xilio Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xilio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xilio Therapeutics and other key companies, straight to your email.

About Xilio Therapeutics

Xilio Therapeutics (NASDAQ:XLO), a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

View Xilio Therapeutics Profile

More Earnings Resources from MarketBeat